Q3 EPS Forecast for TriSalus Life Sciences Cut by Analyst

Key Points

• Northland Capital Markets has lowered its Q3 2025 earnings estimate for TriSalus Life Sciences to ($0.19) per share, down from a previous estimate of ($0.18).
• TriSalus reported Q2 earnings of ($0.27) per share, missing analyst consensus estimates by ($0.05), despite generating $11.21 million in revenue, which surpassed expectations.
• Insider Richard Marshak sold 6,597 shares of TriSalus stock, representing an 8.71% reduction in ownership, as the company experienced a recent stock price decline of 1.8%.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Stock analysts at Northland Capmk decreased their Q3 2025 earnings estimates for shares of TriSalus Life Sciences in a research report issued to clients and investors on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.18). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Northland Capmk also issued estimates for TriSalus Life Sciences' Q4 2025 earnings at ($0.16) EPS.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The company had revenue of $11.21 million during the quarter, compared to analysts' expectations of $10.69 million.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI traded up $0.31 during trading on Friday, hitting $4.86. 112,146 shares of the company were exchanged, compared to its average volume of 82,086. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $5.99. The firm has a market capitalization of $183.90 million, a PE ratio of -4.12 and a beta of 0.48. The company has a fifty day moving average price of $4.77 and a 200-day moving average price of $5.20.

Institutional Trading of TriSalus Life Sciences

Institutional investors have recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $29,000. JPMorgan Chase & Co. raised its position in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after buying an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $47,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of TriSalus Life Sciences during the 1st quarter valued at approximately $55,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at approximately $67,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.